Janssen Submits Supplemental New Drug Application for Zytiga to Treat Metastatic Prostate Cancer
News
Janssen Biotech seeks U.S. approval to use a triple combination treatment with Zytiga (abiraterone acetate), prednisone and androgen deprivation therapy (ADT) for men with high-risk metastatic hormone naïve prostate cancer (HNPC) or ... Read more